M

MDxHealth SA
NASDAQ:MDXH

Watchlist Manager
MDxHealth SA
NASDAQ:MDXH
Watchlist
Price: 1.94 USD 3.74% Market Closed
Market Cap: 96m USD
Have any thoughts about
MDxHealth SA?
Write Note

MDxHealth SA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

MDxHealth SA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
M
MDxHealth SA
NASDAQ:MDXH
Cash & Cash Equivalents
$21.3m
CAGR 3-Years
-12%
CAGR 5-Years
12%
CAGR 10-Years
5%
Galapagos NV
AEX:GLPG
Cash & Cash Equivalents
€52.3m
CAGR 3-Years
-64%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Cash & Cash Equivalents
€3.5m
CAGR 3-Years
-48%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
Cash & Cash Equivalents
€7m
CAGR 3-Years
-16%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
No Stocks Found

MDxHealth SA
Glance View

Market Cap
96m USD
Industry
Biotechnology

MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

MDXH Intrinsic Value
9.14 USD
Undervaluation 79%
Intrinsic Value
Price
M

See Also

What is MDxHealth SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
21.3m USD

Based on the financial report for Jun 30, 2024, MDxHealth SA's Cash & Cash Equivalents amounts to 21.3m USD.

What is MDxHealth SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%

Over the last year, the Cash & Cash Equivalents growth was -46%. The average annual Cash & Cash Equivalents growth rates for MDxHealth SA have been -12% over the past three years , 12% over the past five years , and 5% over the past ten years .

Back to Top